{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:59:41Z","timestamp":1780437581479,"version":"3.54.1"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01632","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:49:47Z","timestamp":1531702187000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature"],"prefix":"10.3389","volume":"9","author":[{"given":"Lei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A. M.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coretta C.","family":"van Leer-Buter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan J. L.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoek A. E.","family":"de Joode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Westra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas A.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10096-016-2605-0","article-title":"Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections","volume":"35","author":"Sauerbrei","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrmicro3215","article-title":"Molecular mechanisms of varicella zoster virus pathogenesis","volume":"12","author":"Zerboni","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40266-012-0014-3","article-title":"Diagnosing and managing postherpetic neuralgia","volume":"29","author":"Nalamachu","year":"2012","journal-title":"Drugs Aging"},{"key":"B4","doi-asserted-by":"publisher","first-page":"004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.07.099","article-title":"Herpes zoster prevention: a difficult problem to solve","author":"Esposito","year":"2017","journal-title":"Vaccine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","article-title":"Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective","volume":"3","author":"Johnson","year":"2015","journal-title":"Ther Adv Vaccines"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1002367","DOI":"10.1371\/journal.ppat.1002367","article-title":"CD4 T cell immunity is critical for the control of Simian varicella virus infection in a nonhuman primate model of VZV infection","volume":"7","author":"Haberthur","year":"2011","journal-title":"PLoS Pathog"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1086\/379048","article-title":"Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine","volume":"188","author":"Levin","year":"2003","journal-title":"J Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/infdis\/jiu500","article-title":"Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection","volume":"211","author":"Schub","year":"2015","journal-title":"J Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1004901","DOI":"10.1371\/journal.ppat.1004901","article-title":"Varicella viruses inhibit interferon-stimulated JAK-STAT signaling through multiple mechanisms","volume":"11","author":"Verweij","year":"2015","journal-title":"PLoS Pathog"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1073\/pnas.1522575113","article-title":"In vitro system using human neurons demonstrates that varicella-zoster vaccine virus is impaired for reactivation, but not latency","volume":"113","author":"Sadaoka","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e00640","DOI":"10.1128\/JVI.00640-17","article-title":"Role of the JNK pathway in varicella-zoster virus lytic infection and reactivation","volume":"91","author":"Kurapati","year":"2017","journal-title":"J Virol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1080\/21645515.2015.1078043","article-title":"Immunizations in solid organ and hematopoeitic stem cell transplant patients: a comprehensive review","volume":"11","author":"L\u2019Huillier","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.transproceed.2012.10.022","article-title":"Evaluation of varicella zoster virus infection morbidity and mortality in pancreas and kidney-pancreas transplant recipients","volume":"45","author":"Netchiporouk","year":"2013","journal-title":"Transplant Proc"},{"key":"B16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1399-3062.2007.00289.x","article-title":"Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis","volume":"10","author":"Arness","year":"2008","journal-title":"Transpl Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1159\/000328730","article-title":"Varicella zoster infection in renal transplant recipients: prevalence, complications and outcome","volume":"34","author":"Mustapic","year":"2011","journal-title":"Kidney Blood Press Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1399-3062.2010.00547.x","article-title":"Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients","volume":"13","author":"Pergam","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12879-015-1038-1","article-title":"Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis","volume":"15","author":"Pavlopoulou","year":"2015","journal-title":"BMC Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/tri.13076","article-title":"Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count. A single-center cohort study","volume":"31","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Transpl Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/tid.12425","article-title":"Incidence and risk factors for herpes zoster in patients undergoing liver transplantation","volume":"17","author":"Hamaguchi","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.healun.2007.09.028","article-title":"Incidence and clinical characteristics of herpes zoster after lung transplantation","volume":"27","author":"Manuel","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"B23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.athoracsur.2008.11.004","article-title":"Herpes zoster after lung transplantation: incidence, timing, and outcome","volume":"87","author":"Fuks","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.healun.2016.04.009","article-title":"Herpes zoster after lung transplantation boosts varicella zoster virus-specific adaptive immune responses","volume":"35","author":"van Besouw","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"B25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/tid.12149","article-title":"Incidence and risk factors for herpes zoster following heart transplantation","volume":"16","author":"Koo","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/ajt.12107","article-title":"Varicella zoster virus in solid organ transplantation","volume":"13","author":"Pergam","year":"2013","journal-title":"Am J Transplant"},{"key":"B27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jinf.2008.03.004","article-title":"Chickenpox in adults \u2013 clinical management","volume":"57","author":"Tunbridge","year":"2008","journal-title":"J Infect"},{"key":"B28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3810\/pgm.2013.09.2703","article-title":"Herpes zoster: diagnostic, therapeutic, and preventive approaches","volume":"125","author":"Bader","year":"2013","journal-title":"Postgrad Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jdv.13995","article-title":"European consensus-based (S2k) guideline on the management of herpes zoster \u2013 guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 1: diagnosis","volume":"31","author":"Werner","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"261947","DOI":"10.1155\/2014\/261947","article-title":"Detection of herpes simplex and varicella-zoster virus in clinical specimens by multiplex real-time PCR and melting curve analysis","volume":"2014","author":"Hong","year":"2014","journal-title":"Biomed Res Int"},{"key":"B31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jviromet.2015.12.009","article-title":"Development of a multiplex real-time PCR for the simultaneous detection of herpes simplex and varicella zoster viruses in cerebrospinal fluid and lesion swab specimens","volume":"229","author":"Wong","year":"2016","journal-title":"J Virol Methods"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1128\/JCM.06753-11","article-title":"Should varicella-zoster virus culture be eliminated? A comparison of direct immunofluorescence antigen detection, culture, and PCR, with a historical review","volume":"50","author":"Wilson","year":"2012","journal-title":"J Clin Microbiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.diagmicrobio.2014.11.012","article-title":"Evaluation of 2 multiplex real-time PCR assays for the detection of HSV-1\/2 and varicella zoster virus directly from clinical samples","volume":"81","author":"Heaton","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/PDM.0b013e3182914291","article-title":"Development and clinical validation of a multiplex real-time PCR assay for herpes simplex and varicella zoster virus","volume":"22","author":"Tan","year":"2013","journal-title":"Diagn Mol Pathol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/1743-422X-7-165","article-title":"A systematic approach for the identification of novel, serologically reactive recombinant varicella-zoster virus (VZV) antigens","volume":"7","author":"Vizoso Pinto","year":"2010","journal-title":"Virol J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1017\/S0950268816000595","article-title":"The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay","volume":"144","author":"Maple","year":"2016","journal-title":"Epidemiol Infect"},{"key":"B37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5501\/wjv.v5.i3.97","article-title":"Microbiology laboratory and the management of mother-child varicella-zoster virus infection","volume":"5","author":"De Paschale","year":"2016","journal-title":"World J Virol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jcv.2009.07.014","article-title":"Varicella-zoster virus CNS disease \u2013 viral load, clinical manifestations and sequels","volume":"46","author":"Persson","year":"2009","journal-title":"J Clin Virol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1002\/art.38804","article-title":"Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases","volume":"66","author":"Rondaan","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jdv.13957","article-title":"European consensus-based (S2k) guideline on the management of herpes zoster \u2013 guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 2: treatment","volume":"31","author":"Werner","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bjp.0706446","article-title":"Antiviral prodrugs \u2013 the development of successful prodrug strategies for antiviral chemotherapy","volume":"147","author":"De Clercq","year":"2006","journal-title":"Br J Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"15; quiz ITC316","DOI":"10.7326\/0003-4819-154-5-201103010-01003","article-title":"In the clinic. Herpes zoster","volume":"154","author":"Wilson","year":"2011","journal-title":"Ann Intern Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia","volume":"43","author":"Styczynski","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"B44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/(SICI)1099-081X(199805)19:4<209::AID-BDD93>3.0.CO;2-O","article-title":"Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats","volume":"19","author":"Sinko","year":"1998","journal-title":"Biopharm Drug Dispos"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1517\/14656566.2010.494179","article-title":"Valacyclovir: approved and off-label uses for the treatment of herpes virus infections in immunocompetent and immunocompromised adults","volume":"11","author":"Vigil","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"B46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.4103\/0378-6323.66577","article-title":"Acyclovir versus valacyclovir","volume":"76","author":"Rajalakshmi","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1081\/CNV-100000070","article-title":"A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients","volume":"19","author":"Tyring","year":"2001","journal-title":"Cancer Invest"},{"key":"B48","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1358\/dot.2003.39.5.740221","article-title":"Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing","volume":"39","author":"Rabasseda","year":"2003","journal-title":"Drugs Today"},{"key":"B49","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/jmv.1890460315","article-title":"Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial","volume":"46","author":"Wutzler","year":"1995","journal-title":"J Med Virol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/rmv.1787","article-title":"Antiviral drug resistance in herpesviruses other than cytomegalovirus","volume":"24","author":"Piret","year":"2014","journal-title":"Rev Med Virol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1111\/ajt.14192","article-title":"Preventive strategies against cytomegalovirus and incidence of \u03b1-herpesvirus infections in solid organ transplant recipients: a Nationwide Cohort Study","volume":"17","author":"Martin-Gandul","year":"2017","journal-title":"Am J Transplant"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1586\/eri.12.115","article-title":"Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients","volume":"10","author":"Bacigalupo","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/j.transproceed.2009.02.093","article-title":"Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases","volume":"41","author":"Ar","year":"2009","journal-title":"Transplant Proc"},{"key":"B54","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/jac\/dkv342","article-title":"Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?","volume":"71","author":"Billat","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"B55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/JPR.S57242","article-title":"Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider","volume":"7","author":"Massengill","year":"2014","journal-title":"J Pain Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11916-016-0548-x","article-title":"Post-herpetic neuralgia: a review","volume":"20","author":"Hadley","year":"2016","journal-title":"Curr Pain Headache Rep"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur J Neurol"},{"key":"B58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-540-79090-7_1","article-title":"Neuropathic pain: a clinical perspective","volume-title":"Sensory Nerves","author":"Baron","year":"2009"},{"key":"B59","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2165\/11632660-000000000-00000","article-title":"Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west","volume":"35","author":"Ogawa","year":"2012","journal-title":"Drug Saf"},{"key":"B60","first-page":"556","article-title":"Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials","volume":"80","author":"Meng","year":"2014","journal-title":"Minerva Anestesiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.clinthera.2010.07.014","article-title":"Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study","volume":"32","author":"P\u00e9rez","year":"2010","journal-title":"Clin Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40780-015-0032-5","article-title":"Opioid analgesics increase incidence of somnolence and dizziness as adverse effects of pregabalin: a retrospective study","volume":"1","author":"Ohishi","year":"2015","journal-title":"J Pharm Health Care Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S0149-2918(03)80111-X","article-title":"The use of gabapentin for the treatment of postherpetic neuralgia","volume":"25","author":"Singh","year":"2003","journal-title":"Clin Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1185\/03007990903047880","article-title":"5% Lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study","volume":"25","author":"Baron","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"B65","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1600-0404.2010.01433.x","article-title":"5% Lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review","volume":"123","author":"Wolff","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"B66","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/11533310-000000000-00000","article-title":"Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis","volume":"30","author":"Ritchie","year":"2010","journal-title":"Clin Drug Investig"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40122-015-0034-x","article-title":"5% lidocaine medicated plaster for the treatment of postherpetic neuralgia: a review of the clinical safety and tolerability","volume":"4","author":"Navez","year":"2015","journal-title":"Pain Ther"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1185\/03007995.2010.483675","article-title":"Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study","volume":"26","author":"Rehm","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"B69","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3810\/pgm.2013.07.2690","article-title":"Evidence-based guidance for the management of postherpetic neuralgia in primary care","volume":"125","author":"Harden","year":"2013","journal-title":"Postgrad Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jdermsci.2015.05.011","article-title":"VZV skin-test reaction, but not antibody, is an important predictive factor for postherpetic neuralgia","volume":"79","author":"Imoto","year":"2015","journal-title":"J Dermatol Sci"},{"key":"B71","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1741-7015-8-37","article-title":"The impact of herpes zoster and post-herpetic neuralgia on quality-of-life","volume":"8","author":"Johnson","year":"2010","journal-title":"BMC Med"},{"key":"B72","first-page":"1528","article-title":"Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B73","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1517\/14712598.2013.830101","article-title":"Zostavax: a subcutaneous vaccine for the prevention of herpes zoster","volume":"13","author":"Doan","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"S236","DOI":"10.1086\/522159","article-title":"Vaccination against herpes zoster and postherpetic neuralgia","volume":"197","author":"Oxman","year":"2008","journal-title":"J Infect Dis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B78","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B79","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/infdis\/jiv480","article-title":"Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults","volume":"213","author":"Levin","year":"2016","journal-title":"J Infect Dis"},{"key":"B80","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/QCO.0000000000000078","article-title":"Immunizations following solid-organ transplantation","volume":"27","author":"Kumar","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"B81","first-page":"4","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"B82","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/ajh.22196","article-title":"Experience with use of Zostavax((R)) in patients with hematologic malignancy and hematopoietic cell transplant recipients","volume":"87","author":"Naidus","year":"2012","journal-title":"Am J Hematol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bbmt.2013.11.013","article-title":"Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients","volume":"20","author":"Issa","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0112-x","article-title":"Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation","author":"Pandit","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e12874","DOI":"10.1111\/tid.12874","article-title":"A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation","volume":"20","author":"Miller","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"B86","first-page":"153","article-title":"Recombinant subunit vaccines: potentials and constraints","volume":"121","author":"Clark","year":"2005","journal-title":"Dev Biol (Basel)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","article-title":"Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults","volume":"34","author":"Chlibek","year":"2016","journal-title":"Vaccine"},{"key":"B90","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","article-title":"Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults","volume":"178","author":"Le","year":"2018","journal-title":"JAMA Intern Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2017.1329012","article-title":"Vaccine profile of herpes zoster (HZ\/su) subunit vaccine","volume":"16","author":"Cunningham","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"B94","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.antiviral.2017.01.011","article-title":"Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis","volume":"140","author":"Seo","year":"2017","journal-title":"Antiviral Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.bbmt.2016.12.620","article-title":"Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies","volume":"23","author":"Sahoo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B96","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/03007995.2017.1384374","article-title":"Herpes zoster incidence and cost in patients receiving autologous hematopoietic stem-cell transplant","volume":"34","author":"Mao","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"B97","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s12185-015-1810-4","article-title":"Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation","volume":"102","author":"Kawamura","year":"2015","journal-title":"Int J Hematol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1586\/14760584.2013.844651","article-title":"The role of VariZIG in pregnancy","volume":"12","author":"Bapat","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B99","first-page":"574","article-title":"Updated recommendations for use of VariZIG \u2013 United States, 2013","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B100","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1017\/S0950268816001485","article-title":"Varicella-zoster immunoglobulin treatment in pregnant women in Denmark from 2005 to 2015: descriptive epidemiology and follow-up","volume":"144","author":"Jespersen","year":"2016","journal-title":"Epidemiol Infect"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.transproceed.2006.08.060","article-title":"Varicella infection in adult renal allograft recipients: experience at one center","volume":"38","author":"Rodriguez-Moreno","year":"2006","journal-title":"Transplant Proc"},{"key":"B102","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00467-010-1666-z","article-title":"Aciclovir and varicella-zoster-immunoglobulin in solid-organ transplant recipients","volume":"26","author":"Prelog","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jcv.2009.09.014","article-title":"Management of varicella contacts in pregnancy: VZIG or vaccination?","volume":"46","author":"Troughton","year":"2009","journal-title":"J Clin Virol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1016\/j.transproceed.2012.09.090","article-title":"Disseminated varicella zoster virus infection in adult renal transplant recipients: outcome and risk factors","volume":"44","author":"Rommelaere","year":"2012","journal-title":"Transplant Proc"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/j.amepre.2016.08.029","article-title":"Herpes zoster vaccine coverage in older adults in the U.S., 2007-2013","volume":"52","author":"Zhang","year":"2017","journal-title":"Am J Prev Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01632\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T04:23:44Z","timestamp":1532060624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01632\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":105,"alternative-id":["10.3389\/fimmu.2018.01632"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01632","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"article-number":"1632"}}